Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

Tubular glucose reabsorption is performed by the combined action of Na + /D-glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) is a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio renal risks.

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

Empagliflozin is the second in the class of medicines called SGLT-2 inhibitors to come off patent ... is propelling people to take immediate action for curing or manage diabetes.

A similar treatment effect of Vanrafia was seen in an additional group of patients treated with both an RAS inhibitor and an SGLT2 inhibitor ... Price Action: NVS stock is up 2.16% at $113. ...